This post-authorization observational safety study determines the characteristics of patients
prescribed naloxegol at time of first prescription and treatment patterns of naloxegol in
follow-up in the United Kingdom (UK), Norway, Sweden, and Germany.
Details
Lead Sponsor:
AstraZeneca Kyowa Kirin Pharmaceutical Development Ltd